|1.||Gao, Weimin: 3 articles (01/2015 - 06/2011)|
|2.||Denkert, Carsten: 3 articles (01/2011 - 02/2008)|
|3.||Buckendahl, Ann-Christin: 3 articles (01/2011 - 02/2008)|
|4.||Weichert, Wilko: 3 articles (01/2011 - 02/2008)|
|5.||Noske, Aurelia: 3 articles (01/2011 - 02/2008)|
|6.||Dietel, Manfred: 3 articles (01/2011 - 02/2008)|
|7.||Yoshida, Minoru: 3 articles (01/2008 - 01/2003)|
|8.||Cha, Jeong-Dan: 2 articles (08/2014 - 05/2011)|
|9.||Cha, In-Ho: 2 articles (08/2014 - 05/2011)|
|10.||Cobos, Everardo: 2 articles (01/2012 - 06/2011)|
01/01/2015 - "Our previous studies have shown Leptomycin B (LMB) is a promising antilung cancer drug. "
04/15/2008 - "Because it was demonstrated previously that blocking of CRM1 by leptomycin B (LMB) contributes to the inhibition of nuclear export, the authors used a set of mechanistic assays to study the effects of CRM1 inhibition in cancer cells. "
09/01/2015 - "Therapeutic targeting of CRM1 has emerged as a novel cancer treatment strategy, starting with a clinical trial with leptomycin B, the original specific inhibitor of CRM1, followed by development of several next-generation small molecules. "
08/01/2014 - "Similarly, leptomycin B (LMB) treatment resulted in the effective killing of oesophageal cancer cells at nanomolar concentrations. "
08/15/2004 - "Blocking export with leptomycin B induces accumulation of both endogenous cIAP1 and epitope-tagged cIAP1 and cIAP2 in the nucleus of human cancer cells. "
|2.||Lung Neoplasms (Lung Cancer)
01/01/2012 - "Our previous study has shown leptomycin B (LMB) significantly inhibited proliferation of lung cancer cells; however, p53 wild type lung cancer cells were resistant to LMB. "
01/01/2015 - "Epigallocatechin-3-gallate enhances the therapeutic effects of leptomycin B on human lung cancer a549 cells."
01/01/2012 - "Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin."
|3.||Hematologic Neoplasms (Hematological Malignancy)
03/10/2008 - "EGFP-X11s were not detected in the nucleus of N2a neuroblastoma cells; however, administration of leptomycin B (LMB) induced substantial nuclear accumulation of EGFP-X11L and EGFP-X11L2, while EGFP-X11 showed little accumulation. "
12/02/1999 - "Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B."
03/15/1999 - "This report also demonstrates that the cytoplasmic localization of p53 in neuroblastoma cells is due to its hyperactive nuclear export: p53 in these cells can be trapped in the nucleus by the export-inhibiting drug leptomycin B or by binding a p53-tetramerization domain peptide that masks the NES. "
08/04/2000 - "In agreement with this observation, treatment of mouse neuroblastoma cells with leptomycin B to inhibit nuclear protein export by exportin1 resulted in accumulation of RGS4 in the nucleus of these cells. "
|1.||Small Interfering RNA (siRNA)
|2.||Messenger RNA (mRNA)
|3.||Nuclear Export Signals (Nuclear Export Signal)
|4.||Nuclear Proteins (Protein, Nuclear)
|6.||Interleukin-1alpha (Interleukin 1 alpha)
|7.||alpha Catenin (alpha E-Catenin)
|8.||JNK Mitogen-Activated Protein Kinases
|9.||Estrogen Receptor alpha
|10.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)